As a levered product, CURE is not a buy-and-hold ETF, it's a short-term tactical instrument. Like many levered funds, it delivers 3x exposure only for one day. Over longer periods, returns can vary significantly from 3x of its underlying index, which covers some of the biggest healthcare nameslike J&J, Pfizer, and Merckin the space, and those heavyweights comprise a large share of CURE's cap-weighted, S&P 500-only portfolio. As a short-term product, CURE's expense ratio is less important than all in trading costs. Trading can be volatile. Check the latest Tradability data on this page.